

Jonathan G Pol

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6393909/jonathan-g-pol-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

3,417
citations

33
h-index

57
g-index

89
ext. papers

4,309
ext. citations

8.7
avg, IF

5.34
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 73 | Improved Swiss-rolling method for histological analyses of colon tissue.. <i>MethodsX</i> , 2022 , 9, 101630 | 1.9 | 1 |
| 72 | NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma.. <i>Molecular Therapy - Oncolytics</i> , 2022 , 24, 695-706 | 6.4 | 0 |
| 71 | Circular RNAs as Potential Biomarkers in Breast Cancer.. <i>Biomedicines</i> , 2022 , 10, | 4.8 | 1 |
| 70 | Local anesthetics elicit immune-dependent anticancer effects. 2022 , 10, | | 1 |
| 69 | Trial watch: intratumoral immunotherapy. <i>OncolImmunology</i> , 2021 , 10, 1984677 | 7.2 | 7 |
| 68 | Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13, | 6.6 | 6 |
| 67 | Valeur pronostique et prédictive de l'Immunoscore dans les cancers du cœlon et de la vessie. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2021 , N° 2, 113-118 | 0.1 | |
| 66 | A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423 | 24.4 | 12 |
| 65 | Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. <i>OncolImmunology</i> , 2021 , 10, 1968595 | 7.2 | 0 |
| 64 | Tumor-intrinsic determinants of immunogenic cell death modalities. <i>OncolImmunology</i> , 2021 , 10, 1893466 | 6.2 | 12 |
| 63 | Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021 , 218, | 16.6 | 4 |
| 62 | Alternative splicing of viral transcripts: the dark side of HBV. <i>Gut</i> , 2021 , 70, 2373-2382 | 19.2 | 3 |
| 61 | Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). <i>Cell Death and Disease</i> , 2020 , 11, 502 | 9.8 | 10 |
| 60 | Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy 2020 , 8, | | 24 |
| 59 | Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11622 | 12 | 31 |
| 58 | Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. <i>Methods in Molecular Biology</i> , 2020 , 2058, 191-211 | 1.4 | 5 |
| 57 | The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome. <i>Pharmacological Research</i> , 2020 , 161, 105249 | 16.2 | 8 |

| | | | |
|----|---|------|----|
| 56 | Dynamical Boolean Modeling of Immunogenic Cell Death. <i>Frontiers in Physiology</i> , 2020 , 11, 590479 | 4.6 | 5 |
| 55 | Autophagy-mediated metabolic effects of aspirin. <i>Cell Death Discovery</i> , 2020 , 6, 129 | 6.9 | 8 |
| 54 | Cytokines in oncolytic virotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020 , 56, 4-27 | 17.9 | 16 |
| 53 | Repurposing CD8 T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. <i>OncImmunology</i> , 2020 , 9, 1794424 | 7.2 | 5 |
| 52 | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020 , 11, 3819 | 17.4 | 41 |
| 51 | Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning 2020 , 8, | | 10 |
| 50 | Immune contexture of cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2020 , 36, 70-76 | 3 | 8 |
| 49 | Effects of interleukin-2 in immunostimulation and immunosuppression. <i>Journal of Experimental Medicine</i> , 2020 , 217, | 16.6 | 46 |
| 48 | A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>OncImmunology</i> , 2019 , 8, e1657375 | 7.2 | 38 |
| 47 | Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl β -Ketoglutarate. <i>Cell Reports</i> , 2019 , 27, 820-834.e9 | 10.6 | 22 |
| 46 | Tumor lysis with LTX-401 creates anticancer immunity. <i>OncImmunology</i> , 2019 , 8, 1594555 | 7.2 | 14 |
| 45 | Trial watch: dietary interventions for cancer therapy. <i>OncImmunology</i> , 2019 , 8, 1591878 | 7.2 | 28 |
| 44 | Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019 , 10, 1486 | 17.4 | 95 |
| 43 | Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. <i>Cell Metabolism</i> , 2019 , 30, 754-767.e9 | 24.6 | 40 |
| 42 | The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. <i>Cancers</i> , 2019 , 11, | 6.6 | 54 |
| 41 | Une triade synergique de chimiothérapie, d'inhibiteurs de points de contrôle immunitaire et de mimétiques de la restriction calorique éradique des tumeurs dans un modèle préclinique murin. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2019 , N° 4, 394 | 0.1 | |
| 40 | Anticancer effects of anti-CD47 immunotherapy. <i>OncImmunology</i> , 2019 , 8, 1550619 | 7.2 | 19 |
| 39 | Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. <i>Methods in Molecular Biology</i> , 2019 , 1884, 297-315 | 1.4 | 31 |

| | | | |
|----|---|------|-----|
| 38 | Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. <i>OncolImmunology</i> , 2019 , 8, e1512329 | 7.2 | 38 |
| 37 | Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance 2018 , 215-229 | | 2 |
| 36 | Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. <i>Trends in Immunology</i> , 2018 , 39, 209-221 | 14.4 | 96 |
| 35 | Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018 , 9, 654 | 8.4 | 27 |
| 34 | HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. <i>Cell Reports</i> , 2018 , 24, 642-654 | 10.6 | 11 |
| 33 | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>OncolImmunology</i> , 2018 , 7, e1503032 | 7.2 | 50 |
| 32 | Metabolic vulnerability of cisplatin-resistant cancers. <i>EMBO Journal</i> , 2018 , 37, | 13 | 52 |
| 31 | Development and applications of oncolytic Maraba virus vaccines. <i>Oncolytic Virotherapy</i> , 2018 , 7, 117-128 | | 24 |
| 30 | Trial watch: Peptide-based vaccines in anticancer therapy. <i>OncolImmunology</i> , 2018 , 7, e1511506 | 7.2 | 90 |
| 29 | Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. <i>OncolImmunology</i> , 2018 , 7, e1484980 | 7.2 | 19 |
| 28 | Metabolic effects of fasting on human and mouse blood in vivo. <i>Autophagy</i> , 2017 , 13, 567-578 | 10.2 | 51 |
| 27 | Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017 , 280, 165-174 | 11.3 | 52 |
| 26 | Customized Viral Immunotherapy for HPV-Associated Cancer. <i>Cancer Immunology Research</i> , 2017 , 5, 847-859 | 10.2 | 29 |
| 25 | Trial watch: DNA-based vaccines for oncological indications. <i>OncolImmunology</i> , 2017 , 6, e1398878 | 7.2 | 22 |
| 24 | Autophagy induction for the treatment of cancer. <i>Autophagy</i> , 2016 , 12, 1962-1964 | 10.2 | 44 |
| 23 | Trial Watch-Oncolytic viruses and cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1117740 | 7.2 | 76 |
| 22 | First oncolytic virus approved for melanoma immunotherapy. <i>OncolImmunology</i> , 2016 , 5, e1115641 | 7.2 | 181 |
| 21 | Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016 , 30, 147-160 | 24.3 | 285 |

| | | | |
|----|---|------|-----|
| 20 | Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. <i>Journal of Immunology</i> , 2016 , 196, 4587-95 | 5.3 | 30 |
| 19 | S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. <i>Nature Immunology</i> , 2016 , 17, 514-522 | 19.1 | 45 |
| 18 | Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e1008866 | 7.2 | 162 |
| 17 | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , 2015 , 4, e985940 | 7.2 | 38 |
| 16 | Trial Watch: Peptide-based anticancer vaccines. <i>OncolImmunology</i> , 2015 , 4, e974411 | 7.2 | 81 |
| 15 | Alternative splicing-regulated protein of hepatitis B virus hacks the TNF- β -stimulated signaling pathways and limits the extent of liver inflammation. <i>FASEB Journal</i> , 2015 , 29, 1879-89 | 0.9 | 17 |
| 14 | Consensus guidelines for the detection of immunogenic cell death. <i>OncolImmunology</i> , 2014 , 3, e955691 | 7.2 | 524 |
| 13 | Trial Watch: Radioimmunotherapy for oncological indications. <i>OncolImmunology</i> , 2014 , 3, e954929 | 7.2 | 36 |
| 12 | Trial Watch: DNA vaccines for cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e28185 | 7.2 | 33 |
| 11 | Trial Watch:: Oncolytic viruses for cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e28694 | 7.2 | 88 |
| 10 | Maraba virus as a potent oncolytic vaccine vector. <i>Molecular Therapy</i> , 2014 , 22, 420-429 | 11.7 | 106 |
| 9 | Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. <i>Molecular Therapy</i> , 2014 , 22, 123-31 | 11.7 | 77 |
| 8 | Trial watch: Dendritic cell-based anticancer therapy. <i>OncolImmunology</i> , 2014 , 3, e963424 | 7.2 | 54 |
| 7 | HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. <i>Molecular Therapy</i> , 2013 , 21, 887-94 | 11.7 | 85 |
| 6 | Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. <i>Cancer Immunology Research</i> , 2013 , 1, 309-19 | 12.5 | 54 |
| 5 | Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines. <i>OncolImmunology</i> , 2013 , 2, e26013 | 7.2 | 45 |
| 4 | Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. <i>Blood</i> , 2013 , 121, 2432-9 | 2.2 | 31 |
| 3 | Oncolytic viruses: a step into cancer immunotherapy. <i>Virus Adaptation and Treatment</i> , 2011 , 1 | | 2 |

| | | | |
|---|--|-----|----|
| 2 | Prospective comparison of Abbott RealTime HBV DNA and Versant HBV DNA 3.0 assays for hepatitis B DNA quantitation: impact on HBV genotype monitoring. <i>Journal of Virological Methods</i> , 2008 , 154, 1-6 | 2.6 | 7 |
| 1 | Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. <i>Journal of Infectious Diseases</i> , 2008 , 198, 218-25 | 7 | 42 |